MMP9 and hematocrit: The high concentration of MMP‐9 in plasma or MMP‐9 mRNA concentration within the acute phase of IS increases the risk of HT (Montaner et al., 2001), and is a predictor of poor outcomes and mortality in patients with IS (Graham et al., 2012).